文献速递真菌感染医院感染防控

ICU 侵袭性霉菌感染:复杂性与解决方案

Invasive mould infections in the ICU setting: complexities and solutions.
PubMed 文献 · J Antimicrob Chemother · 2017-01-01

综述聚焦 ICU 中丝状真菌感染,指出侵袭性曲霉病在非中性粒细胞减少的易感人群中日益增多,诊断困难且常延迟;疑似即应启动伏立康唑或艾沙康唑治疗。毛霉病罕见但增多,多见于糖尿病控制不佳等患者,需控制基础病、快速手术切除及脂质体两性霉素 B 治疗,病死率仍很高。

要点

  • ICU 非中性粒细胞减少患者侵袭性曲霉病增多,诊断常延迟。
  • 疑似侵袭性曲霉病即应启动伏立康唑或艾沙康唑,不等确诊。
  • 毛霉病需控制基础病、快速手术切除及脂质体两性霉素 B。

核心结论

  • ICU 中丝状真菌感染负担重,侵袭性曲霉病在非中性粒细胞减少者中增多且诊断困难。
  • 疑似侵袭性曲霉病应不等确诊即启动伏立康唑或艾沙康唑治疗。
  • 毛霉病在 ICU 中比例高,尽管诊治进步病死率仍很高。

研究设计与样本

  • 综述,检索范围未在摘要中报告。

主要发现

  • 侵袭性曲霉病在非中性粒细胞减少者中增多,易感条件包括糖皮质激素治疗、慢阻肺、肝硬化、实体瘤、HIV 感染和移植。
  • ICU 患者呼吸道分离曲霉及血清半乳甘露聚糖、BAL 1-3-β-d-葡聚糖和特异性 PCR 结果需谨慎解读。
  • 毛霉病主要见于糖尿病控制不佳、免疫抑制者或伤口被毛霉目污染者,表现为鼻窦、肺或皮肤软组织快速进展的坏死性病变。
  • 毛霉病确诊基于组织内非分隔菌丝侵袭及新的分子技术。
  • 毛霉病治疗包括控制基础病、快速手术切除和脂质体两性霉素 B,艾沙康唑为有前景的替代。

关键数值与推荐

  • 疑似侵袭性曲霉病时 ICU 患者应启动充分抗真菌治疗,无需等待确诊证据。
  • 伏立康唑和艾沙康唑是侵袭性曲霉病的首选药物。
  • 毛霉病主要治疗为控制基础病、快速手术切除及脂质体两性霉素 B。

临床怎么用

  • 对 ICU 中具备糖皮质激素治疗、慢阻肺、肝硬化、实体瘤、HIV 或移植等条件的患者保持侵袭性曲霉病警惕。
  • 呼吸道曲霉分离及半乳甘露聚糖、BAL 1-3-β-d-葡聚糖、PCR 结果需结合临床谨慎解读。
  • 疑似侵袭性曲霉病即启动伏立康唑或艾沙康唑,不等待确诊。
  • 对糖尿病控制不佳或免疫抑制患者出现鼻窦、肺或皮肤软组织快速坏死性病变,应排查毛霉病并尽早手术和抗真菌治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Infections caused by filamentous fungi represent a major burden in the ICU. Invasive aspergillosis is emerging in non-neutropenic individuals with predisposing conditions, e.g. corticosteroid treatment, chronic obstructive pulmonary disease, liver cirrhosis, solid organ cancer, HIV infection and transplantation. Diagnosis is challenging because the signs and symptoms are non-specific, and initiation of additional diagnostic examinations is often delayed because clinical suspicion is low. Isolation of an Aspergillus species from the respiratory tract in critically ill patients, and tests such as serum galactomannan, bronchoalveolar lavage 1-3-β-d-glucan and specific PCR should be interpreted with caution. ICU patients should start adequate antifungal therapy upon suspicion of invasive aspergillosis, without awaiting definitive proof. Voriconazole, and now isavuconazole, are the drugs of choice. Mucormycosis is a rare, but increasingly prevalent disease that occurs mainly in patients with uncontrolled diabetes mellitus, immunocompromised individuals or previously healthy patients with open wounds contaminated with Mucorales. A high proportion of cases are diagnosed in the ICU. Rapidly progressing necrotizing lesions in the rhino-sinusal area, the lungs or skin and soft tissues are the characteristic presentation. Confirmation of diagnosis is based on demonstration of tissue invasion by non-septate hyphae, and by new promising molecular techniques. Control of underlying predisposing conditions, rapid surgical resection and administration of liposomal amphotericin B are the main therapeutic actions, but new agents such as isavuconazole are a promising alternative. Patients with mucormycosis receive a substantial part of their care in ICUs and, despite advances in diagnosis and treatment, mortality remains very high.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Bassetti M, Bouza E. Invasive mould infections in the ICU setting: complexities and solutions. J Antimicrob Chemother. 2017. PMID: 28355466. doi:10.1093/jac/dkx032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。